News & Updates
Filter by Specialty:
Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo
Data presented at ESMO Gyn 2025 support apixaban as a prophylactic agent for venous thromboembolism (VTE) in women with epithelial ovarian cancer who are undergoing neoadjuvant chemotherapy consisting of carboplatin and paclitaxel.
Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo
09 Sep 2025
Second cancers may develop in women with early invasive breast cancer
Women treated for early invasive breast cancer have a slightly higher risk of a second primary cancer than those in the general population, reveals a study. Such risk is greater among younger women.
Second cancers may develop in women with early invasive breast cancer
08 Sep 2025
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
05 Sep 2025
Supplemental imaging strategies facilitate early cancer detection in women with dense breasts
Supplemental breast cancer (BC) imaging techniques may help detect early cancers that standard mammograms may have missed in women with dense breasts, according to interim results from the BRAID* trial.
Supplemental imaging strategies facilitate early cancer detection in women with dense breasts
05 Sep 2025
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.
